ASM joined the Infectious Diseases Society of America (IDSA) and the Pan American Society for Clinical Virology (PASCV) in drafting comments for the draft Diagnostic Accuracy and Innovation Act (DAIA) legislation.  The DAIA builds upon previous efforts to establish a new framework for the regulation of both in vitro diagnostic tests and laboratory-developed tests (LDTs).

ASM and the Pan American Society of Clinical Virology (PASCV) drafted a letter expressing concerns about the turnaround time for results in the Zika plaque reduction neutralizing test (PRNT) currently available and suggested some solutions.   


Joomla! Debug Console


Profile Information

Memory Usage

Database Queries